CAGE Bio

Executive Summary

CAGE Bio is a clinical-stage biotechnology company developing localized treatments for dermatological and inflammatory conditions using its proprietary deep eutectic ionic liquid (DEIL) platform. This innovative technology enables the topical delivery of potent small and large molecules, aiming to achieve systemic-level efficacy while minimizing systemic side effects. The company is initially focused on immuno-dermatology, with its lead program targeting vitiligo, a chronic autoimmune condition causing skin depigmentation. CAGE Bio's approach addresses a significant unmet need, as current vitiligo treatments have limited efficacy or safety concerns. Founded in 2017 and headquartered in Cambridge, MA, the company has generated preclinical data supporting its platform's ability to enhance drug penetration and stability, positioning it as a potential game-changer in topical therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead vitiligo program70% success
• H1 2027Announcement of next indication or pipeline expansion40% success
• 2027Potential strategic partnership for platform technology30% success